arrow
A

Angela DeMichele

center for clinical epidemiology and biostatistics
H指数:89
被引数:2.8万

个人简介

暂无内容

教育背景

  • 1988.12

    Brown University B.A. Biochemistry

  • 1991.12

    Washington University School of Medicine M.D. Medicine

  • 2001.12

    University of Pennsylvania, School of Medicine M.S.C.E. Clinical Epidemiology

工作经历

暂无内容

荣誉奖项

暂无内容

A multi-dimensional framework for predicting taxane-induced peripheral neuropathy in Black women with breast cancer: findings from ECOG-ACRIN EAZ171

一种用于预测黑种乳腺癌女性紫杉烷诱导性周围神经病变的多维框架:ECOG-ACRIN EAZ171研究的结果

2026-08-260
OAAI
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171

黑种人乳腺癌患者报告的紫杉烷类诱导周围神经病变对剂量减少或生活质量恶化的影响:ECOG-ACRIN EAZ171研究分析

Cancer
IF5.1
2026-05-290
OAAI
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer

外周血转录组分析预测人乳腺癌的肿瘤亚型及新辅助化免治疗效果

2026-04-220
PRE
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort

HER2低表达和超低表达乳腺癌的临床与分子学评估:PENELOPE-B临床试验队列研究

2026-04-210
PRE
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

循环肿瘤DNA细化新辅助治疗耐药乳腺肿瘤的危险分层

2025-12-090
OAAI
DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer

DTC-Flow:一种基于流式细胞术的检测平台,用于表征乳腺癌中骨髓播散性肿瘤细胞

2025-11-240
OAAI
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

CHFR 表达以及乳腺癌细胞在体外和I-SPY试验中对抗有丝分裂剂敏感性

2025-10-240
OA
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

帕博西利联合辅助内分泌疗法在早期乳腺癌中的应用:全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析

2025-10-170
OAAI
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)

EA1211: DIRECT试验:中期FDG-PET/CT预测HER2阳性乳腺癌对新辅助治疗的反应

2025-10-050
PRE
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial

靶向休眠肿瘤细胞以预防复发性乳腺癌:一项随机Ⅱ期临床试验

2025-09-020
PRE
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

ASO视觉摘要:新辅助化疗后至手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-290
PRE
Correction: Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome

更正:通过对自我报告种族的导管原位癌进行分析,揭示了与结局相关的分子差异

2025-08-290
OAAI
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

新辅助化疗后手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-230
PRE
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

ASO视觉摘要:新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化率的影响:根据I-SPY2临床试验中分子高风险肿瘤的组织学亚型进行分析

2025-08-230
PRE
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化影响的评估:基于I-SPY2临床试验中按组织学亚型分析分子高风险肿瘤

2025-07-240
OA
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

在多中心新辅助I-SPY2试验中,基于自我识别种族的腋窝手术管理差异

2025-07-230
OA
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

HER2DX和早期HER2阳性乳腺癌的生存结局:一项基于个体患者水平的荟萃分析

2025-07-140
PRE
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
2025-03-010
PRE